KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Tax Provisions (2016 - 2025)

Pacira BioSciences (PCRX) has 13 years of Tax Provisions data on record, last reported at -$1.1 million in Q4 2025.

  • For Q4 2025, Tax Provisions fell 111.24% year-over-year to -$1.1 million; the TTM value through Dec 2025 reached $9.8 million, down 73.01%, while the annual FY2025 figure was $9.8 million, 73.01% down from the prior year.
  • Tax Provisions reached -$1.1 million in Q4 2025 per PCRX's latest filing, down from $4.1 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $17.7 million in Q2 2024 and bottomed at -$8.0 million in Q4 2022.
  • Average Tax Provisions over 5 years is $3.9 million, with a median of $4.0 million recorded in 2025.
  • Peak YoY movement for Tax Provisions: surged 15025.0% in 2021, then plummeted 1588.84% in 2023.
  • A 5-year view of Tax Provisions shows it stood at -$1.1 million in 2021, then crashed by 645.88% to -$8.0 million in 2022, then skyrocketed by 211.1% to $8.8 million in 2023, then rose by 7.18% to $9.5 million in 2024, then tumbled by 111.24% to -$1.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Tax Provisions were -$1.1 million in Q4 2025, $4.1 million in Q3 2025, and $2.9 million in Q2 2025.